3rd Chair and Department of Cardiology, Medical University of Silesia in Katowice, School of Medicine with the Division of Dentistry in Zabrze, Silesian Center for Heart Diseases, Poland.
Kardiol Pol. 2017;75(4):332-343. doi: 10.5603/KP.a2017.0013. Epub 2017 Feb 2.
Impairment of renal function (IRF) is an independent risk factor of myocardial infarction (MI).
The aim of study was to determine if the presence of IRF affects the choice of treatment strategy in patients with MI, and if long-term mortality rates are influenced by the use of an invasive strategy in patients with MI according to the grade of IRF.
Data from the PL-ACS Registry of 22,431 patients hospitalised for MI during 2007-2008 with an available estimated glomerular filtration rate (eGFR) with 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula were included. Patients were stratified based on eGFR: ≥ 90 (normal); 60-89 (mild IRF); 30-59 (moderate IRF); 15-29 (severe IRF); and < 15 mL/min/1.73 m² (end-stage IRF).
After adjustment, each increase in IRF grade reduced the likelihood of percutaneous coronary intervention by 19% (odds ratio [OR] 0.81; 95% confidence interval [CI] 0.78-0.85; p < 0.001). A higher IRF grade was independently associated with mortality (OR 2.01; 95% CI 1.86-2.18; p < 0.001) and major bleeding (OR 1.42; 95% CI 1.22-1.66; p < 0.001) during hospitalisation, and mortality at 12 (hazard ratio [HR] 1.55; 95% CI 1.49-1.62; p < 0.001) and 36 months (HR 1.50; 95% CI 1.45-1.55; p < 0.001). Invasive treatment was independently associated with improved 12-month prognosis in non-ST-segment elevation MI (NSTEMI) patients with mild-to-severe IRF and in ST-elevation MI (STEMI) patients at all IRF grades.
Invasive procedures were less frequent with worsening renal dysfunction. Invasive treatment was associ-ated with improved 12-month prognosis in STEMI patients regardless of renal function and in NSTEMI patients with eGFR ≥ 15 mL/min/1.73 m².
肾功能障碍(IRF)是心肌梗死(MI)的独立危险因素。
本研究旨在确定 IRF 是否影响 MI 患者的治疗策略选择,以及根据 IRF 程度,MI 患者使用侵入性策略是否会影响长期死亡率。
纳入了 2007-2008 年期间因 MI 住院且可获得 2009 年慢性肾脏病流行病学合作(CKD-EPI)公式估计肾小球滤过率(eGFR)的 22431 例患者的 PL-ACS 登记处数据。根据 eGFR 将患者分层:≥90(正常);60-89(轻度 IRF);30-59(中度 IRF);15-29(重度 IRF);<15 mL/min/1.73 m²(终末期 IRF)。
调整后,IRF 等级每增加一级,经皮冠状动脉介入治疗的可能性降低 19%(比值比 [OR] 0.81;95%置信区间 [CI] 0.78-0.85;p<0.001)。较高的 IRF 等级与住院期间的死亡率(OR 2.01;95%CI 1.86-2.18;p<0.001)和主要出血(OR 1.42;95%CI 1.22-1.66;p<0.001)独立相关,并且在 12 个月(危险比 [HR] 1.55;95%CI 1.49-1.62;p<0.001)和 36 个月(HR 1.50;95%CI 1.45-1.55;p<0.001)时的死亡率也独立相关。侵入性治疗与非 ST 段抬高型心肌梗死(NSTEMI)患者中轻度至重度 IRF 患者以及所有 IRF 等级的 ST 段抬高型心肌梗死(STEMI)患者的 12 个月预后改善相关。
肾功能障碍越严重,侵入性治疗的可能性越低。侵入性治疗与 STEMI 患者 12 个月的预后改善相关,无论肾功能如何,与 eGFR≥15 mL/min/1.73 m²的 NSTEMI 患者的预后改善相关。